<DOC>
	<DOCNO>NCT00100685</DOCNO>
	<brief_summary>This clinical trial conduct determine tumor response preliminary safety monoclonal antibody specifically bind cell surface receptor ( α5β1 integrin ) require establishment new blood vessel tumor growth , process know angiogenesis .</brief_summary>
	<brief_title>Study M200 ( Volociximab ) Patients With Metastatic Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Males females least 18 year age metastatic RCC predominantly clear cell histology receive 0 2 prior treatment regimens metastatic disease . Measurable disease accord Response Criteria Solid Tumors . Negative pregnancy test ( woman childbearing potential ) . Pretreatment laboratory level meet specific criterion . Signed date informed consent authorization use protect health information ( accordance national local patient privacy regulation Patients must fail least one approve investigational tyrosine kinase inhibitor ( TKI ) . Exclusion Criteria Any follow histology RCC : papillary , chromophobe , collect duct , unclassified . Known sensitivity murine proteins chimeric antibody component product . Use investigational drug within 4 week prior screen 5 halflives prior investigational drug ( whichever longer ) . Systemic chemotherapy , immunotherapy , radiation therapy , monoclonal antibody therapy within 4 week M200 administration . Documented central nervous system ( CNS ) tumor CNS metastasis . History thromboembolic event bleed disorder within past year . Medical condition may exacerbate bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Kidney</keyword>
	<keyword>renal</keyword>
	<keyword>cancer</keyword>
	<keyword>carcinoma</keyword>
	<keyword>cell</keyword>
	<keyword>metastatic</keyword>
	<keyword>metastatic renal cell carcinoma</keyword>
	<keyword>RCC</keyword>
</DOC>